Mycobacterium Avium Subsp. Paratuberculosis

The dosage of Mycobacterium Avium Subsp. Paratuberculosis extract is highly individualized and depends on the specific diagnostic protocol being followed.

• Intradermal Testing: The standard adult dose is typically 0.1 mL of a specific dilution (e.g., 1:100 or 1:1000 w/v). The injection is administered into the volar surface of the forearm using a 26- or 27-gauge needle. The goal is to produce a small, distinct bleb (skin elevation) of 6 to 10 mm in diameter.
• Epicutaneous (Prick) Testing: A single drop of the concentrated extract is applied to the skin, which is then pricked with a sterile lancet. This is usually performed before intradermal testing to rule out extreme hypersensitivity.

Mycobacterium Avium Subsp. Paratuberculosis extract is not routinely approved for pediatric use unless specifically indicated by an immunologist or infectious disease specialist.

• Children (under 18): If used, the dosage is often adjusted to a lower volume (e.g., 0.02 mL to 0.05 mL) to minimize the risk of a severe local reaction. However, safety and efficacy in the pediatric population have not been established through large-scale clinical trials.

Renal Impairment

No dosage adjustment is typically required for patients with renal impairment, as the systemic absorption of the extract is negligible. However, patients with end-stage renal disease (ESRD) may exhibit 'anergy' (a lack of immune response), which can lead to false-negative results.

Hepatic Impairment

No dosage adjustment is required for hepatic impairment. Similar to renal issues, severe liver disease may alter the patient's immune status, potentially affecting the interpretation of the skin test.

Elderly Patients

Elderly patients may have thinned skin (atrophy), which requires careful needle insertion to avoid subcutaneous injection (which would invalidate the test). Additionally, age-related decline in T-cell function (immunosenescence) may result in smaller reaction sizes.

This agent is never self-administered. It must be administered by a healthcare professional in a clinical setting equipped to handle emergency allergic reactions.

1. 1Preparation: The skin site (usually the forearm) is cleaned with an alcohol swab and allowed to dry.
2. 2Administration: The healthcare provider will perform the injection or prick. You must remain in the clinic for at least 30 minutes following the procedure to monitor for immediate allergic reactions (anaphylaxis).
3. 3Reading the Results: You must return to the clinic exactly 48 to 72 hours after the injection. The provider will measure the 'induration' (the hard, raised area), not the 'erythema' (the redness).
4. 4Storage: The extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It should never be frozen and must be protected from light.

Since this is a diagnostic test, a 'missed dose' refers to a missed reading appointment. If you do not have the skin site measured within the 48-to-72-hour window, the test is considered invalid and must be repeated. A waiting period of at least 2 to 4 weeks is usually recommended before re-testing at a different skin site to avoid the 'booster effect.'

An overdose of an allergenic extract involves either the administration of too high a volume or too high a concentration.

• Signs: Severe local swelling, blistering (vesiculation), tissue necrosis (death of skin tissue), or a systemic reaction such as hives, wheezing, or drop in blood pressure.
• Emergency Measures: If a systemic reaction occurs, epinephrine is the first-line treatment. Cold compresses may be applied to the site to slow absorption. In cases of severe local necrosis, specialized wound care may be required.

> Important: Follow your healthcare provider's dosing instructions. Do not attempt to interpret or measure your own skin reaction; medical guidance is essential for an accurate diagnosis.

Most patients receiving Mycobacterium Avium Subsp. Paratuberculosis extract will experience some form of local reaction, which is often the intended result of the test.

• Erythema (Redness): A red area surrounding the injection site is very common. This usually appears within hours and may persist for several days.
• Induration (Hardness): A firm, raised bump at the injection site is the hallmark of a positive DTH response. It may feel slightly tender or tight.
• Pruritus (Itching): The injection site may itch significantly as the immune response develops. Patients are advised not to scratch the area, as this can cause secondary infection or alter the test results.
• Tenderness: Light pressure on the site may cause mild discomfort.

• Persistent Pigmentation: In some patients, the skin at the injection site may remain darker (hyperpigmentation) for several weeks or months after the test.
• Lymphadenopathy: Swelling of the lymph nodes in the axilla (armpit) on the side of the injection may occur as the immune system processes the antigen.
• Malaise: Some patients report feeling generally tired or 'flu-like' for 24 hours following the injection.

• Vesiculation and Ulceration: In highly sensitive individuals, the center of the skin reaction may blister or break open, leading to a small sore or ulcer.
• Scarring: If an ulceration occurs, it may leave a small, permanent scar.
• Fever: A low-grade fever may occur as part of a systemic immune activation.

While rare with diagnostic extracts, systemic allergic reactions are possible and can be life-threatening.

> Warning: Stop the procedure and call your doctor or emergency services immediately if you experience any of the following:

• Anaphylaxis: A severe, whole-body allergic reaction characterized by a rapid pulse, difficulty breathing, and a sharp drop in blood pressure.
• Angioedema: Swelling of the lips, tongue, or throat that can obstruct the airway.
• Generalized Urticaria: Hives that spread far beyond the injection site to other parts of the body.
• Wheezing or Bronchospasm: Sudden chest tightness or whistling sounds when breathing.
• Syncope (Fainting): Feeling dizzy or passing out shortly after the injection.

There are no known long-term systemic side effects associated with a single diagnostic use of Mycobacterium Avium Subsp. Paratuberculosis extract. The primary long-term concern is 'sensitization,' where the test itself causes the patient to become allergic to the substance, potentially leading to a more severe reaction if the test is repeated in the future.

Although Mycobacterium Avium Subsp. Paratuberculosis is a non-standardized extract, it falls under the general class of allergenic extracts which carry significant safety warnings.

FDA-Style Warning Summary: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylactic shock and death. They should only be administered by physicians who are exceptionally familiar with the use of allergenic extracts and the treatment of emergency allergic reactions. Patients should be observed for at least 30 minutes after administration. Patients with unstable asthma or those taking beta-blockers may be at higher risk for severe outcomes if a reaction occurs.

Report any unusual symptoms, especially those occurring within the first hour of injection, to your healthcare provider immediately.

Mycobacterium Avium Subsp. Paratuberculosis extract is a potent biological agent. Its use is restricted to diagnostic or research settings. The most critical safety consideration is the risk of an immediate systemic hypersensitivity reaction. Patients must provide a full medical history, specifically focusing on previous reactions to skin tests or vaccines, before the extract is administered.

No specific FDA black box warning exists uniquely for 'Mycobacterium Avium Subsp. Paratuberculosis' as a standalone entity, but it is covered under the General Black Box Warning for Allergenic Extracts:

"Allergenic extracts may cause severe systemic reactions, including fatal anaphylaxis. This product should be prescribed and administered only by physicians who are experienced in the treatment of allergic diseases and are equipped to manage such reactions. Patients should be observed for at least 30 minutes in the office after an injection. More severe reactions may occur in patients with bronchial asthma, particularly if it is not well-controlled."

• Anaphylaxis Risk: This is the primary concern. Facilities must have an 'emergency kit' containing epinephrine (1:1000), antihistamines, and oxygen readily available.
• Asthma: Patients with active or poorly controlled asthma are at a significantly higher risk for severe respiratory complications if a systemic reaction occurs. The test may need to be postponed if the patient is experiencing an asthma flare.
• Bleeding Disorders: Because the extract is injected intradermally, patients with hemophilia or those taking high-dose anticoagulants (blood thinners) may experience significant bruising or hematoma at the site.
• Infection at Site: The extract should never be injected into skin that is sunburned, infected, or affected by active eczema or psoriasis, as this can interfere with the reading and increase the risk of secondary infection.

• Immediate Observation: The patient must be monitored for 30 minutes post-injection for signs of Type I hypersensitivity (hives, itching, shortness of breath).
• Delayed Observation: The patient must return at 48-72 hours for a professional reading of the induration.
• Baseline Health: Vital signs (blood pressure, heart rate) may be taken before the test to ensure the patient is stable.

Generally, this test does not affect the ability to drive or operate machinery. However, if a patient experiences a systemic reaction or feels faint (vasovagal response) after the injection, they should not drive until cleared by a medical professional.

While there is no direct chemical interaction between alcohol and the MAP extract, alcohol consumption can cause vasodilation (widening of blood vessels), which might increase the redness or itching at the skin test site. It is advisable to avoid heavy alcohol use for 48 hours following the test.

There is no 'discontinuation' or 'tapering' required for a single-dose diagnostic test. If a patient is undergoing a series of tests and experiences a severe reaction, the testing protocol must be stopped immediately.

> Important: Discuss all your medical conditions, especially any history of severe allergies or asthma, with your healthcare provider before starting Mycobacterium Avium Subsp. Paratuberculosis testing.

• Live Viral Vaccines: Administering a skin test like MAP at the same time as live vaccines (such as MMR or Varicella) may interfere with the immune response. It is generally recommended to wait 4 to 6 weeks after a live vaccine before performing a DTH skin test.
• High-Dose Immunosuppressants: Drugs like cyclophosphamide or high-dose methotrexate may completely suppress the T-cell response, rendering the test useless and potentially misleading.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications do not interact with the MAP extract itself, but they block the effects of epinephrine. If the patient has an anaphylactic reaction to the skin test, epinephrine may not work effectively, making the reaction much harder to treat.
• ACE Inhibitors (e.g., Lisinopril): Similar to beta-blockers, ACE inhibitors may worsen the severity of an anaphylactic reaction and complicate emergency treatment.

• Systemic Corticosteroids (e.g., Prednisone): Oral or IV steroids suppress the cellular immune response. Patients taking more than 15mg of prednisone daily may show a 'false negative' result because the drug prevents the T-cells from creating the skin induration.
• H1-Antihistamines (e.g., Cetirizine, Diphenhydramine): These drugs suppress the 'wheal and flare' (immediate) reaction. While they have less effect on the 48-hour delayed reaction, they can mask early warning signs of a systemic allergic reaction.

There are no known direct food interactions with Mycobacterium Avium Subsp. Paratuberculosis extract. However, patients should maintain their normal diet to avoid confounding symptoms (like an upset stomach) that could be confused with a systemic reaction.

• Immune-Modulating Herbs: Supplements like Echinacea, Astragalus, or high-dose Elderberry may theoretically alter the immune response. It is best to discontinue these 1 week prior to diagnostic testing.
• St. John’s Wort: While primarily known for CYP interactions, its effect on general inflammation might subtly influence skin test sensitivity.

• Tuberculin Skin Test (PPD): Because MAP is closely related to Mycobacterium tuberculosis, a skin test for MAP may cause a 'booster' effect or cross-reactivity with a PPD test. If both are needed, they should be performed at the same time or separated by several weeks.
• Interferon-Gamma Release Assays (IGRAs): The use of MAP extract might theoretically cause a transient increase in circulating IFN-gamma, though this is rarely clinically significant for blood tests like QuantiFERON-TB Gold.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect your immune system or blood pressure.

Mycobacterium Avium Subsp. Paratuberculosis must NEVER be used in the following circumstances:

• Previous Severe Reaction: Any history of anaphylaxis or severe local necrosis following exposure to MAP or other mycobacterial extracts (like PPD).
• Active Skin Infection: The presence of cellulitis, impetigo, or extensive dermatitis at the site of testing, as this poses a risk of spreading the infection and prevents accurate reading.
• Known Hypersensitivity to Phenol: Most non-standardized extracts use phenol as a preservative. Patients with a known allergy to phenol must not receive these products.

Healthcare providers must perform a careful risk-benefit analysis in these cases:

• Unstable Asthma: If the patient's forced expiratory volume (FEV1) is significantly below their baseline, the risk of a fatal reaction increases.
• Acute Viral or Bacterial Infection: A current illness can cause temporary 'anergy' or immunosuppression, leading to a false-negative result. It is usually best to wait until the patient has been recovered for 2 to 4 weeks.
• Recent Live Vaccine: As noted in the interactions, recent vaccination can interfere with T-cell responses.
• Pregnancy: While not strictly contraindicated, testing should be deferred unless the diagnostic information is critical for the management of the mother's health.

Patients who are sensitive to other members of the Mycobacterium family, such as M. tuberculosis, M. leprae, or M. avium-intracellulare, are highly likely to show cross-reactivity with MAP. This is due to the shared protein antigens (such as heat shock proteins) across the genus. This cross-sensitivity is a primary reason why the test must be interpreted by a specialist who can differentiate between a specific reaction and a cross-reactive one.

> Important: Your healthcare provider will evaluate your complete medical history, including any past skin tests, before prescribing or administering Mycobacterium Avium Subsp. Paratuberculosis.

Mycobacterium Avium Subsp. Paratuberculosis extract is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm or affect reproduction capacity.

• Risks: The primary risk during pregnancy is not the extract itself, but the potential for a systemic anaphylactic reaction in the mother, which could lead to fetal hypoxia (lack of oxygen).
• Clinical Decision: Testing should only be performed during pregnancy if the potential benefit clearly outweighs the potential risk to the fetus.

It is not known whether the components of Mycobacterium Avium Subsp. Paratuberculosis extract are excreted in human milk. However, since the dose is minute and administered locally into the skin, systemic levels in the mother are expected to be extremely low.

• Precaution: While the risk to the nursing infant is likely negligible, healthcare providers should monitor the infant for any unusual skin rashes or changes in feeding behavior if the mother undergoes extensive testing.

Safety and effectiveness in children under the age of 18 have not been established.

• Immune Maturity: The cellular immune system in infants (under 1 year) is still developing, which may lead to unreliable results.
• Risk of Reaction: Children with a history of severe atopic dermatitis or multiple food allergies may be at a higher risk for more pronounced local reactions.

Clinical studies of allergenic extracts generally do not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

• Skin Integrity: Fragile skin in the elderly can lead to the extract being injected too deeply (subcutaneously) or leaking out, both of which invalidate the test.
• Reduced Response: A negative result in an elderly patient must be interpreted with caution, as the DTH response naturally wanes with age.

Patients with chronic kidney disease (CKD), particularly those on dialysis, often have impaired T-cell function. This can result in a 'false negative' skin test. No dosage adjustment is needed, but the clinical interpretation must account for the patient's uremic state.

There are no specific studies on MAP extract in patients with hepatic impairment. However, severe cirrhosis is known to cause lymphopenia (low white blood cell count), which can diminish the skin test response.

> Important: Special populations require individualized medical assessment and careful monitoring during and after the administration of any allergenic extract.

Mycobacterium Avium Subsp. Paratuberculosis (MAP) extract functions as a diagnostic antigen that probes the effector arm of the cell-mediated immune system. The specific molecular mechanism involves the recognition of MAP-specific proteins, such as the PtpA and PtpB (protein tyrosine phosphatases) and the IS900 gene products, by sensitized T-lymphocytes.

Upon intradermal injection, these antigens are captured by Langerhans cells in the epidermis. These cells migrate to the regional lymph nodes and present the antigen to CD4+ T-cells. If the patient has been previously exposed to MAP, memory T-cells are activated and migrate back to the site of injection. There, they secrete cytokines like IL-2 and IFN-gamma. This creates a local inflammatory cascade characterized by vasodilation and the accumulation of mononuclear cells, resulting in the palpable induration measured at 48-72 hours.

• Dose-Response: There is a clear dose-response relationship; higher concentrations of the extract will produce larger areas of induration, up to a plateau.
• Time to Onset: The immediate (IgE-mediated) response occurs within 15-30 minutes, but the diagnostic (T-cell mediated) response takes 24-48 hours to become visible.
• Duration of Effect: The physical skin reaction typically resolves within 7 to 10 days, though the immunological 'priming' can last for years.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Local administration) |

| Protein Binding | N/A (Local tissue binding) |

| Half-life | 24-48 hours (at injection site) |

| Tmax | 48-72 hours (for clinical effect) |

| Metabolism | Local Proteolysis |

| Excretion | Lymphatic Clearance |

• Composition: A complex mixture of water-soluble proteins, glycoproteins, and polysaccharides extracted from the cell wall and cytoplasm of Mycobacterium avium subsp. paratuberculosis.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various protein fractions.
• Solubility: Soluble in aqueous buffers; typically provided in a 0.9% saline solution with 0.4% phenol.
• Structure: Non-crystalline, biological polymer mixture.

MAP belongs to the class of Non-Standardized Allergenic Extracts. It is related to other mycobacterial products like Tuberculin (PPD) and Lepromin. Unlike standardized extracts (like those for grass pollen or dust mites), MAP does not have a federally mandated 'Bioequivalent Unit' (BAU) or 'Allergy Unit' (AU) rating in the United States, meaning its potency is determined by the weight of the raw material per volume of diluent (w/v).